Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.

However, after everolimus treatment, there was a significant reduction in CECs number only in responders, resulting in a highly significant different numbers between responders and non-responders ( p < 0.001), demonstrating the biological activity of everolimus.

also in 132,142 other papers